Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Diabetic Foot Ulcer Therapeutics Pipeline Analysis, 2017

P&S Market Research-Diabetic Foot Ulcers Therapeutics Pipeline Analysis report

Diabetic Foot Ulcer Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: July 2017
Report Code: LS11103
Available Format: pdf
Pages: 128

Disease Overview

Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Currently, the prevalence of diabetic foot ulcer in diabetic population of the U.S. stands at 4% to 10%. Among diabetic foot ulcer patients, it is estimated that majority (around 60% to 80%) of foot ulcer are capable to heal, while 10% to 15% remain active and around 5% to 24% of them can lead to limb amputation within a period of 6-18 months. Diabetic foot ulcer is associated with neuropathic wounds as well as neuroischemic wounds. The neuropathic wounds are more likely to heal whereas, neuroischemic wounds take longer to heal, and can more often lead to amputation of the respective limb. Many studies have reported that, approximately 85% of all amputations performed in diabetic patients are caused by diabetic foot ulcer. Duration of diabetes and age of the diabetic patients further increase the risk of diabetic foot ulcer and limb amputation.

Pipeline Analysis

Considerable growth is expected in the diabetic foot ulcer therapeutic pipeline, attributed to increasing prevalence of diabetes. According to the World Health Organization, the prevalence of diabetes among adults over 18 years of age, has risen from 4.7% in 1980 to 8.5% in 2014, in the U.S. Funds received or raised from various non-profit organizations such as, American Podiatric Medical Association and PAN Association, are being used to support the development of therapeutic pipeline of the diabetic foot ulcer. Many technological advancements are also contributing towards the development of diabetic foot ulcer therapeutics pipeline.

As of July 2017, the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.

Number of DIABETIC FOOT ULCER drug candidates under Development (2017)

Diabetic Foot Ulcer Therapeutics Pipeline Analysis

Competitive Landscape

Some of the key players developing drugs for the treatment of diabetic foot ulcer include Lakewood Amedex, Inc., Edixomed Ltd., CardioVascular BioTherapeutics Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment